Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Bispecific T cell engagers (TCE) targeting BCMA or GPRC5D have improved outcomes in relapsed/refractory multiple myeloma (MM), yet up to 40% of patients are primarily refractory, and predictive biomarkers are scarce. To address this unmet clinical need, we developed an image-based, high-content ex vivo assay using patient-derived bone marrow mononuclear cells exposed to teclistamab or talquetamab.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
